This was stated by a Boston biotech company Moderna.

Boston biotech company Moderna, which is today the leader in the development of vaccines against coronavirus COVID-19, announced that the drug mRNA-1273 passed the first tests on humans and demonstrated high efficiency,

45 patients aged 18 to 55 years, were introduced for 25, 100, and 250 milligrams of the experimental drug. After the secondary injection of antigen to those who received doses of 25 and 100 milligrams was discovered antibodies in quantities exceeding natural resulting illnesses.

This was reported on Monday, may 18, in a press release from the Moderna Inc . CEO Stefan Bansal said in an interview with American news Agency Bloomberg that the results have surpassed the most courageous expectations of the researchers.

He stressed that an experimental vaccine mRNA-1273, generally safe and well tolerated by patients. Further testing will begin in July.

Note that today the shares of Moderna soared by 26% in the previous auction.